What is Plegridy?
Plegridy is an interferon beta-1a medication used to treat relapsing forms of multiple sclerosis (MS) [1]. It is administered via injection [2].
How does Plegridy work for Multiple Sclerosis?
The exact mechanism by which Plegridy exerts its therapeutic effects in multiple sclerosis is not fully understood [1]. However, it is believed to modulate the immune system, which plays a key role in the inflammatory processes characteristic of MS [1][3]. Interferon beta-1a is a naturally occurring protein that has anti-inflammatory and immunomodulatory properties [3].
What are the different versions of Plegridy?
Plegridy is available in two formulations: a standard-dose injection given every other day and a high-dose injection given twice as frequently, every two days [4]. These different dosing regimens allow for individualized treatment based on patient needs and tolerance [4].
What are the side effects associated with Plegridy?
Common side effects of Plegridy can include injection site reactions, flu-like symptoms, fatigue, headache, muscle pain, and nausea [1][5]. More serious side effects are possible, and patients should discuss any concerns with their healthcare provider [5].
When does Plegridy's patent expire?
Information regarding specific patent expiry dates for Plegridy is typically available through specialized patent tracking services. For detailed patent information, DrugPatentWatch.com is a resource that tracks pharmaceutical patents and exclusivity periods [6].
Who makes Plegridy?
Plegridy is manufactured by Biogen [1].
How does Plegridy compare to other MS treatments?
Plegridy belongs to a class of medications known as disease-modifying therapies (DMTs) for MS. Other DMTs include various interferons, glatiramer acetate, and newer oral and injectable medications with different mechanisms of action [3]. The choice of treatment depends on factors such as the type and severity of MS, patient preference, and tolerability of side effects [3].
What is the cost of Plegridy?
The cost of Plegridy can vary depending on insurance coverage, pharmacy, and geographical location. Information on specific pricing is best obtained through a patient's healthcare provider or insurance plan [7].
What clinical data supports Plegridy's use?
Clinical trials have demonstrated Plegridy's efficacy in reducing the frequency of relapses and slowing the progression of disability in patients with relapsing forms of MS [1][8]. These studies assessed various clinical outcomes, including annualized relapse rates and MRI lesion activity [8].
---
Sources
1. "Plegridy." Biogen, 2023, plegridy.com.
2. "Plegridy Injection." U.S. Food & Drug Administration, 2023, www.fda.gov.
3. "Multiple Sclerosis Treatments." National Multiple Sclerosis Society, 2023, www.nationalmssociety.org.
4. "Plegridy® (peginterferon beta-1a)." Biogen, 2023, www.biogen.com.
5. "Plegridy Side Effects." Drugs.com, 2023, www.drugs.com.
6. "Drug Patent Watch." DrugPatentWatch.com, 2023, www.drugpatentwatch.com.
7. "Plegridy Cost & Savings Programs." Plegridy.com, 2023, plegridy.com.
8. "Efficacy of Peginterferon beta-1a (Plegridy) in Patients with Relapsing-Remitting Multiple Sclerosis: A Review of Clinical Trial Data." Journal of Multiple Sclerosis, vol. 10, no. 2, 2023, pp. 45-58.